Hemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands

Similar documents
HEMOSTASIS AND LIVER DISEASE. P.M. Mannucci. Scientific Direction, IRCCS Ca Granda Foundation Maggiore Hospital, Milan, Italy

Management of Cirrhotic Patients Undergoing Non-Transplant Surgery

Chapter 3. Haemostatic abnormalities in patients with liver disease

DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin

A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients

Review Article Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate

TRANSFUSIONS FIRST, DO NO HARM

World Journal of Pharmaceutical Research SJIF Impact Factor 5.990

University of Groningen. Blood platelets in liver transplantation Pereboom, Ilona Tapke Annie

Thrombocytopenia and Chronic Liver Disease

Index. Note: Page numbers of article titles are in boldface type.

Appendix 3 PCC Warfarin Reversal

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Hemostasis, Disorders of Coagulation and Transfusion in Cirrhosis

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Management of Challenging Bleeding: Patients with Coagulopathy

Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD

Bleeding, Coagulopathy, and Thrombosis in the Injured Patient

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Massive Transfusion. MPQC Spring Summit April 29, Roger Belizaire MD PhD

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

Blood Transfusion Guidelines in Clinical Practice

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011

Assessment of coagulation abnormalities associated with liver diseases

Bleeding risk with invasive procedures in patients with cirrhosis and coagulopathy

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY

BLEEDING DISORDERS Simple complement:

Index. Note: Page numbers of article titles are in boldface type.

Effect of under filling tube

Challenges in Perioperative. Coagulopathy in Elective and Urgent Cardiac Surgery

Hemostatic derangement in Dengue infection

Heme (Bleeding and Coagulopathies) in the ICU

COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Balanced Transfusion Resuscitation

Recombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients

ADMINISTRATIVE CLINICAL Page 1 of 6

Introduction to coagulation and laboratory tests

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Intraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

Dispelling myths about coagulation abnormalities in internal medicine

Chapter 5. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation

INHERITED COAGULOPATHY

Treatment of Acute Hemorrhagic Stroke 5th QSVS Neurovascular Conference Dar Dowlatshahi MD PhD FRCPC Sept 14, 2012

Hematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Dubbi e certezze nella gestione delle emorragie con metodiche point-of-care

PREDLOG SMERNIC ZA KLINIČNO UPORABE SVEŽE ZMRZNJENE PLAZME Guidelines for clinical use of FFP proposal

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION

THROMBOTIC DISORDERS: The Final Frontier

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)

University of Groningen. Hemostasis and anticoagulant therapy in liver diseases Potze, Wilma

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

TRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES

ACQUIRED COAGULATION ABNORMALITIES

Pathology note 8 BLEEDING DISORDER

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Approach to disseminated intravascular coagulation

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS

Clinical Overview of Coagulation Testing Issues

Hemostasis and Blood Forming Organs

Hemostasis and Thrombosis in Cirrhotic Patients

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

How can ROTEM testing help you in trauma?

Algorithms for managing coagulation disorders in liver disease

How can ROTEM testing help you in cardiac surgery?

Major Haemorrhage Protocol. Commentary

MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS

Acquired Inhibitors of Coagulation

GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital

Managing Bleeding on NOACs

International Journal of Recent Advances in Multidisciplinary Research Vol. 04, Issue 02, pp , February, 2017

New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle

Erratum to: Int J Hematol (2014) 99: DOI /s

Menopausal Hormone Therapy & Haemostasis

Thromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation

The Coagulopathy of Liver Disease: Fair and Rebalanced?

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.

NOACS/DOACS*: COAGULATION TESTS

Index. Note: Page numbers of article titles are in boldface type.

Transfusion strategies in patients with cirrhosis: less is more. 1. Department of Gastroenterology, Hillingdon Hospital, London, UK

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Reversal of Anticoagulants at UCDMC

2019 ReachMD Page 1 of 5

Transcription:

Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands

Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins Thrombopoietin

Hemostatic alterations in liver disease Thrombocytopenia and platelet function defects Low levels of coagulation proteins & inhibitors Low levels of fibrinolytic proteins High VWF, FVIII, tpa, PAI-1

Causes of liver diseases? Cirrhosis Cholestatic Non-cholestatic NAFLD/NASH Acute liver failure Acetaminophen Viral Medication

Hemostatic alterations in liver disease Consequences for labvalues Low platelet count Prolonged PT, APTT

Hemostatic alterations in liver disease Low platelet count Bleeding? Prolonged PT, APTT

Bleeding complications in liver disease Variceal bleeding consequence of portal hypertension and local vascular abnormalities

Bleeding complications in liver disease Procedural bleeding

Bleeding complications during liver transplantation Transfusion. 1987 May-Jun;27(3):222-5: During the first 5 years (1981-1985) of the liver transplantation program in Pittsburgh, a total (preoperative, intraoperative, and postoperative) of 18,668 packed red cell units, 23,627 fresh-frozen plasma units, 20,590 platelet units, and 4241 cryoprecipitate units was transfused for the procedures (626 transplants). This represents 3 to 9 percent of the total of blood products supplied by the Central Blood Bank to its 32 member hospitals.

Disorders of Hemostasis, Ratnoff & Forbes, eds, 1996, 3 rd ed.

Hepatology 2012;55:1634

Bleeding complications during liver transplantation Dig Surg. 2005;22(4):265-75

Transplantation 2012;93:1276

Caveats of routine diagnostic tests of hemostasis Platelet count needs context Thrombocytopenia is common VWF is substantially elevated and compensates in part for the low platelet count Hepatology. 2006; 44:53-61

Caveats of routine diagnostic tests of hemostasis Platelet count needs context Thrombocytopenia is common VWF is substantially elevated and compensates in part for the low platelet count Control Patient Hepatology. 2006; 44:53-61

VWF multimers are cleaved by ADAMTS13 A deficiency of this protein leads to TTP

Reduced ADAMTS13 in cirrhosis Thromb Haemost. 2008 Jun;99(6):1019-29

Caveats of routine diagnostic tests of hemostasis Prothrombin time is only sensitive for VII, X, V, II, fg

Prothrombin time is insensitive for natural anticoagulants (AT, TFPI, PC/PS) No protein C activation during TF-induced coagulation in plasma due to absence of thrombomodulin

Decreased levels of anticoagulants compensate for decreased levels of procoagulants C P C P Hepatology 2005; 41: 553-558

Fibrinolysis in cirrhosis concomitant decrease in pro- and antifibrinolytic factors >200 Clot lysis time (min) 100 0 Control Mild Moderate Severe Gastroenterology. 2001 Jul;121(1):131-9.

Decreased permeability of plasma clots J Thromb Haemost. 2016;14(5):1054-66

Hemostatic balance Bleeding Thrombosis Procoagulants Anticoagulants Healthy individual

Liver disease: Hemostatic rebalance Bleeding Thrombosis Procoagulants Anticoagulants Patient with liver disease

Clinical evidence for rebalanced hemostasis in patients with liver disease Bleeding does occur in patients with cirrhosis. However, the most common bleeding complication bleeding varices is unrelated to hemostasis Liver transplantation a major and lengthy surgical procedure can be performed without any requirements for blood transfusion Patients with liver diseases are not auto-anticoagulated

Clinical consequences of rebalanced hemostasis in patients with cirrhosis Prophylactic transfusion to correct routine laboratory abnormalities (plt count, PT, APTT) to prevent bleeding during invasive procedures is probably of little use Effect of prophylactic transfusion prior to liver transplantation has never been proven Complete correction almost never achieved Transfusion has major side-effects Fluid overload (fuels the fire) Preoperative laboratory tests do not predict bleeding Costs (major indication for FFP & platelets)

Thrombotic complications in cirrhosis Venous thrombosis Hepatic vascular diseases Coronary events Intrahepatic thrombosis

Indications for anticoagulant therapy Venous thrombosis Hepatic vascular diseases Coronary events Intrahepatic thrombosis But: anticoagulants are underused as a result of the preceived bleeding risk

The anti-xa assay underestimates LMWH mass in patients with cirrhosis Br J Haematol. 2013 Dec;163(5):666-73.

Enhanced anticoagulant potency of LMWH in patients with liver disease PLoS One. 2014 Feb 4;9(2):e88390

Coagulation affects fibrogenesis in mice Warfarin Control Factor Vleiden J Thromb Haemost. 2008 Aug;6(8):1336-43

Gastroenterology. 2012 Nov;143(5):1253-60

In summary: Routine laboratory values do not accurately reflect the hemostatic status in cirrhosis The traditional concept that cirrhosis is associated with a hemostasis-related bleeding tendency is no longer valid Laboratory and clinical support for the concept of rebalanced hemostasis Transfusion free transplantation Normal hemostatic status in more sophisticated laboratory tests